MedTrace Logo

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-22

No results posted yet for this study

Summary

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Conditions

  • Refractory Rheumatoid Arthritis (RA)
  • Idiopathic Inflammatory Myopathies (IIMs)
  • Systemic Sclerosis (SSc)
  • Rheumatoid Arthritis (RA
  • IIM
  • Myositis
  • Scleroderma
  • Sjogren Syndrome
  • Sjogrens Disease

Interventions

DRUG

Allogeneic NK Cells

AlloNK, dosed after a conditioning regimen, combined with Rituximab.

Sponsors & Collaborators

  • Artiva Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Saddekni, M.D., PgDip, BCMAS · Artiva Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-09
Primary Completion
2028-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Bulgaria
  • France
  • Germany
  • Italy
  • Poland
  • Portugal
  • Romania
  • Serbia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06991114 on ClinicalTrials.gov